546th Edition, February 22, 2023

BioHealth Innovation, Inc. (BHI) is seeking a half-time Entrepreneur-in-Residence (EIR) to join their team at the National Institutes of Health (NIH). The EIR will provide product, corporate, and private investment strategies for NIH-funded R&D teams and small businesses ready to take the next step toward commercial success.

As the world’s largest early-stage biomedical investor, the NIH is committed to accelerating the conversion of scientific discoveries into healthcare solutions. Working directly with NIH staff and the portfolios of early-stage R&D teams and small businesses to mentor and enable business/product development, they will bring, build, and expand networks with private and corporate investors and related stakeholder organizations with a strategic interest in early-stage biomedical technologies.

The EIR will also support existing initiatives for early-stage product development and ideate, plan, and help to implement new programs. They will engage and partner with investment associations, economic development, and business organizations for additional support to enhance NIH innovators’ commercial success across the US. This role will also present and coordinate investor forums, conferences, and other networking opportunities for early-stage life science companies, scientists, universities, associations, and federal laboratories.

Click here to view and role description.

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. Under the terms of the definitive agreement, Bavarian Nordic will acquire the rights to VIVOTIF®, indicated for the active immunization to prevent typhoid fever, and VAXCHORA®, indicated for the active immunization to prevent cholera, as well as the development-stage chikungunya vaccine candidate CHIKV VLP. Bavarian Nordic will also acquire Emergent’s manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 current Emergent employees are expected to join Bavarian Nordic as part of the transaction.

Maryland business dedicated to developing telehealth solutions for remotely monitoring patients with eye and brain diseases

COLUMBIA, Md. (February 16, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent State Small Business Credit Initiative (SSBCI) investment of $150,000 into JuneBrain Inc., an organization focused on creating new ways for physicians to remotely monitor their patients.

On Friday, Maryland Gov. Wes Moore and Lt. Gov. Aruna Miller came to North Bethesda to meet with local leaders about a new research facility planned for the area.

“In order for this to be Maryland’s decade, it means it also must be Montgomery County’s decade,” Moore said following a meeting with leaders including County Executive Marc Elrich and county councilmembers. “And this is going to be an important component to actually making that happen.”

• If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) —  Today, Emergent BioSolutions Inc. (NYSE:EBS) announced the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee have unanimously voted in favor (a total of 19 votes) that the benefit-risk profile of NARCAN® (naloxone HCl) Nasal Spray is supportive of its use as a nonprescription opioid overdose reversal agent. Emergent presented an overview of its over-the-counter (OTC) development program, the medical need, Human Factors study data and seven years of post-marketing safety data. The FDA is not bound by the committees’ guidance but will take its advice into consideration.

NCI SBIR is hosting an informational webinarExit Disclaimer on funding and resources designed to assist cancer technology innovators get their projects to the market. This presentation is appropriate for both established small businesses and researchers interested in translating technologies to patients and/or marketplace.  Program Directors Sarra Djemil and William Bozza will cover topics, including: